BioCentury
ARTICLE | Company News

NICE FAD recommends J&J's Darzalex through CDF

January 19, 2018 7:36 PM UTC

The U.K.'s NICE issued a final appraisal determination (FAD) recommending that Darzalex daratumumab from Johnson & Johnson (NYSE:JNJ) be covered by the country's Cancer Drugs Fund as monotherapy to treat fourth-line relapsed and refractory multiple myeloma. Previous therapy must have included a proteasome inhibitor and an immunmodulator.

The agency said it will collect cost-effectiveness data through 2020 after which it will review the guidance...

BCIQ Company Profiles

Johnson & Johnson

BCIQ Target Profiles

CD38